Table 4A.

Relationship between contractile function, cardiac biomarkers, QTc interval and myocyte injury in NHP treated chronically with doxorubicin.

NHP#	Dox (mg/kg)	Telemetry unit type	Functional effect or endpoint impacted*
			dP/dT Max	EF	QTc interval	cTnI	NT-pro-BNP	Cardiac injury
104928	16	BP + LVP						Minimal (U)
104929	13	BP + LVP						(S)
104930	16	BP + LVP						Mild (U)
104931	16	BP + LVP						Minimal (S)
104932	11	BP + LVP						Mild (U)
104933	17	BP + LVP						(U)
104934	13	BP	ND					(U)
104935	17	BP	ND					(U)
104936	13	BP	ND					Mild (U)
104937	16	BP	ND		ND			Mild (U)
104938	13	BP	ND					(U)
104939	13	BP	ND					Minimal (U)

^*Cardiac contractility (dP/dtmax derived from LVP): >10% reduction = red; <10% = green. Ejection fraction (EF): >10% reduction = red; <10% = green. QTc interval: >10% prolongation = red; <10% prolongation = green. Troponin (cTnI): ≥2 samples with signal (>0.05 ng/ml) = red; 1/0 samples with signal = green. Natriuretic peptide (NT-pro-BNP): ≥2 samples with signal (>0.05 ng/ml) = red; no signal = green. Cardiac injury: presence of vacuolation = red; no vacuolation = green.

S, Scheduled sacrifice; U, Unscheduled sacrifice.

ND, not determined due to lack of LVP instrumentation or ECG failure.